VALANX Biotech Appoints New Chief Scientific Officer
VALANX Biotech, a biotech company, has appointed Klaus Orlinger, PhD, as Chief Scientific Officer to bolster its leadership team.
Klaus brings over 15 years of industry experience in developing oncology and infectious disease drug candidates.
He will drive the Company's scientific strategy, including the development of its flagship protein conjugation platform, GoldenSite.
This appointment will advance the development of best-in-class therapeutic protein conjugates as the Company progresses its first antibody drug conjugate to candidate selection phase.
Author's summary: VALANX Biotech appoints Klaus Orlinger as CSO.
More News
- Nordic-Baltic regional unity is our biggest advantage - Vucans
- Fashion lovers step out for Carol Byrne X Very Partywear Edit
- Animal Crossing: New Horizons Gets a Free Update and Switch 2 Edition
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- International Architecture Biennial of Antalya (IABA)
- Animal Crossing: New Horizons Getting Switch 2 Edition and Free Content Update
- The myth of a straight Starmer v Farage choice exposed
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Eala falls to Mboko to exit Hong Kong Open